Clinical trials query results
From Health Canada
| Drug name | CTA protocol title | Medical condition | Study population | Trial status |
|---|---|---|---|---|
| BAY 94-9343 (ANETUMAB RAVTANSINE) / VINORELBINE | A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, PHASE II STUDY OF INTRAVENOUS ANETUMAB RAVTANSINE (BAY 94-9343) OR VINORELBINE IN PATIENTS WITH ADVANCED OR METASTATIC MALIGNANT PLEURAL MESOTHELIOMA OVEREXPRESSING MESOTHELIN AND PROGRESSED ON FIRST LINE PLATINUM/ PEMETREXED-BASED CHEMOTHERAPY | MALIGNANT PLEURAL MESOTHELIOMA | ADULT FEMALE,ADULT MALE | CLOSED |
| IAG933/ TECHNETIUM TC 99M | AN OPEN-LABEL, MULTI-CENTER, PHASE I STUDY OF ORAL IAG933 IN ADULT PATIENTS WITH ADVANCED MESOTHELIOMA AND OTHER SOLID TUMORS | SOLID TUMORS,MESOTHELIOMA | ADULT FEMALE,ADULT MALE | ONGOING |
| IMFINZI / TREMELIMUMAB / PROCYTOX | SURGERY FOR MESOTHELIOMA AFTER RADIATION THERAPY USING EXQUISITE SYSTEMIC THERAPY | MESOTHELIOMA | ADULT FEMALE,ADULT MALE | ONGOING |
| KEYTRUDA / ANETUMAB RAVTANSINE / GLUCOVISION | PHASE 1 SAFETY RUN-IN AND PHASE 2 RANDOMIZED CLINICAL TRIAL OF ANETUMAB RAVTANSINE AND MK-3475 (PEMRBOLIZUMAB) COMPARED TO MK-3475 (PEMBROLIZUMAB) ALONE FOR MESOTHELIN-POSITIVE MALIGNANT PLEURAL MESOTHELIOMA | PLEURAL MESOTHELIOMA | ADULT FEMALE,ADULT MALE | ONGOING |
| MK-3475 (PEMBROLIZUMAB) | A PHASE II RANDOMIZED STUDY OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA | PLEURAL MESOTHELIOMA | ADULT FEMALE,ADULT MALE | ONGOING |
| NINTEDANIB (BIBF 1120 ES) | DOUBLE BLIND, RANDOMISED, MULTICENTRE, PHASE II STUDY OF NINTEDANIB IN COMBINATION WITH PEMETREXED / CISPLATIN FOLLOWED BY CONTINUING NINTEDANIB MONOTHERAPY VERSUS PLACEBO IN COMBINATION WITH PEMETREXED / CISPLATIN FOLLOWED BY CONTINUING PLACEBO MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA | MALIGNANT PLEURAL MESOTHELIOMA | ADULT FEMALE,ADULT MALE | CLOSED |
| PEMETREXED/CISPLATIN/CARBOPLATIN | PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS CHEMOTHERAPY WITH OR WITHOUT ADJUVANT HEMITHORACIC INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT) FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM) | MALIGNANT PLEURAL MESOTHELIOMA | ADULT FEMALE,ADULT MALE | CLOSED |
| RAD-IFN (NADOFARAGENE FIRADENOVEC)/ CELECOXIB/ GEMCITABINE | A PHASE III, OPEN LABEL, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAPLEURAL ADMINISTRATION OF ADENOVIRUS-DELIVERED INTERFERON ALPHA-2B (RAD-IFN) IN COMBINATION WITH CELECOXIB AND GEMCITABINE IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA | MALIGNANT PLEURAL MESOTHELIOMA | ADULT FEMALE,ADULT MALE | ONGOING |
| TREMELIMUMAB | A PHASE 2, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING TREMELIMUMAB TO PLACEBO IN SECOND OR THIRD-LINE TREATMENT OF SUBJECTS WITH UNRESECTABLE PLEURAL OR PERITONEAL MALIGNANT MESOTHELIOMA | MALIGNANT PLEURAL MESOTHELIOMA | ADULT FEMALE,ADULT MALE | PENDING |
| VOLRUSTOMIG (MEDI5752) | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL STUDY OF VOLRUSTOMIG (MEDI5752) IN COMBINATION WITH CARBOPLATIN PLUS PEMETREXED VERSUS PLATINUM PLUS PEMETREXED OR NIVOLUMAB PLUS IPILIMUMAB IN PARTICIPANTS WITH UNRESECTABLE PLEURAL MESOTHELIOMA (EVOLVE-MESO) | PLEURAL MESOTHELIOMA | ADULT FEMALE,ADULT MALE | ONGOING |
| VS-6063 | A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF VS 6063 IN SUBJECTS WITH MALIGNANT PLEURAL MESOTHELIOMA | MALIGNANT PLEURAL MESOTHELIOMA | ADULT FEMALE,ADULT MALE | ONGOING |